Piper Sandler analyst Matt O’Brien lowered the firm’s price target on Insulet to $325 from $360 and keeps an Overweight rating on the shares. The company reported strong Q2 results and guidance was raised across nearly all metrics, the analyst tells investors in a research note. The firm recommends investors take advantage of the post-earnings weakness to build positions in the stock.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PODD:
- Insulet price target lowered to $273 from $319 at Citi
- Insulet price target lowered to $330 from $375 at Wells Fargo
- Insulet raises FY23 revenue growth view to 22%-25% from 18%-22%
- Insulet sees Q3 revenue up 18%-21% from last year
- Insulet reports Q2 EPS 38c, consensus 26c
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue